10-K: IGC Pharma Narrows Focus to Life Sciences, Reports Reduced Losses and Positive Alzheimer's Drug Trial Data

IGC Pharma, Inc. has strategically realigned its operations to focus solely on Life Sciences, reporting a significant reduction in net losses and encouraging interim Phase 2 clinical trial results for its lead Alzheimer's drug candidate, IGC-AD1, despite a decrease in overall revenue and cash reserves.

Summary

• IGC Pharma has strategically realigned its business to operate as a single reportable segment focused on Life Sciences, discontinuing its Infrastructure segment which generated no revenue in Fiscal 2025.
• The Company reported a net loss attributable to common stockholders of approximately $7.12 million for Fiscal 2025, a significant decrease from $13 million in Fiscal 2024.
• Overall revenue slightly decreased by $74 thousand to $1.27 million in Fiscal 2025 from $1.345 million in Fiscal 2024, though Life Sciences segment revenue increased from $1.181 million to $1.271 million.
• Selling, general, and administrative (SG&A) expenses decreased by approximately $2.35 million, or 35%, to $4.41 million in Fiscal 2025, reflecting efforts to optimize operational efficiency.
• Research and development (R&D) expenses remained relatively stable at approximately $3.66 million in Fiscal 2025, a 3% decrease from Fiscal 2024, primarily driven by the progression of IGC-AD1 Phase 2 trials and TGR-63 preclinical studies.
• Interim Phase 2 clinical trial data for IGC-AD1 demonstrated a statistically significant reduction in agitation in Alzheimer's patients, with a Cohen-Mansfield Agitation Inventory (CMAI) LS mean difference of -10.46 (p=0.042) and a large effect size (Cohens d=0.79) at week 6.
• IGC-AD1 also showed clinically and statistically significant reductions in sleep disturbances, with a 71% reduction at week 2 (p=0.012) and 78% at week 6 (p=0.02) compared to placebo.
• The Company's cash and cash equivalents decreased by approximately 66% to $405 thousand as of March 31, 2025, from $1.198 million in Fiscal 2024.
• IGC Pharma raised approximately $4.64 million through private equity placements and at-the-market (ATM) offerings in Fiscal 2025.
• The Company is developing Artificial Intelligence (AI)/Machine Learning (ML) models, including MINT-AD, for early Alzheimer's detection and clinical trial optimization.
• IGC Pharma holds a robust intellectual property portfolio with 12 granted patents and 31 pending patent applications across various therapeutic areas.
• The Company disposed of non-core assets, including land in Nagpur, India, which was impaired by approximately $3.3 million in Fiscal 2024 and sold for approximately $701 thousand in Fiscal 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant progress in clinical trials for IGC-AD1, including strong efficacy and safety data, and effective cost management. However, this is tempered by ongoing financial losses, decreased cash reserves, and the inherent high risks associated with drug development in Alzheimer's disease, indicating continued financial challenges despite clinical promise.

Positives

• Net loss significantly decreased by approximately $5.88 million (45%) from $13 million in Fiscal 2024 to $7.12 million in Fiscal 2025.
• Selling, general, and administrative (SG&A) expenses were substantially reduced by 35% (approximately $2.35 million), demonstrating improved cost and cash discipline.
• Positive interim Phase 2 clinical trial results for IGC-AD1 showed a statistically significant reduction in agitation in Alzheimer's patients (CMAI LS mean difference -10.46, p=0.042, Cohens d=0.79) at week 6.
• IGC-AD1 also demonstrated clinically and statistically significant reductions in sleep disturbances (71% at week 2, 78% at week 6) among Alzheimer's patients.
• The safety profile of IGC-AD1 in the Phase 2 trial has been favorable, with no serious adverse events (SAEs), no adverse events (AEs) leading to treatment discontinuation, and no deaths reported.
• The Company has successfully optimized clinical trial operations, achieving a cost per patient enrolled of approximately $70 thousand, significantly below the industry average of $100 thousand to $150 thousand for similar trials.
• Strategic realignment to focus solely on the high-potential Life Sciences segment, including Alzheimer's drug development and AI initiatives.
• Continued investment in Artificial Intelligence (AI) and Machine Learning (ML) for early Alzheimer's detection and clinical trial optimization, including the MINT-AD tool.
• Strong intellectual property portfolio with 12 granted patents and 31 pending patent applications, demonstrating commitment to innovation.
• Appointment of Terry McAuliffe, former Governor of Virginia, as a strategic advisor, enhancing leadership and industry connections.
• Secured a working capital credit facility of $12 million from O-Bank, Co., Ltd., providing additional liquidity.

Negatives

• The Company continues to incur significant net losses, with an accumulated deficit of $120.74 million as of March 31, 2025.
• Cash and cash equivalents decreased significantly by 66% from $1.198 million in Fiscal 2024 to $405 thousand in Fiscal 2025.
• Working capital decreased by 53% from $1.365 million in Fiscal 2024 to $639 thousand in Fiscal 2025.
• Overall revenue decreased by 6% in Fiscal 2025, primarily due to the cessation of the Infrastructure segment's revenue.
• The Company's ability to achieve or sustain profitability is highly uncertain, and it expects to continue incurring substantial expenses for clinical development.
• The Company faces challenges in raising capital as a public company due to its incorrect classification as a 'cannabis company' despite deriving IGC-AD1 from federally legal hemp, leading to blacklisting by some financial institutions.
• Alzheimer's disease drug candidates have a historically high failure rate of approximately 99.6%, posing significant development risk.
• The Company acknowledges its inexperience in conducting preclinical and clinical trials, which could lead to unanticipated or adverse outcomes.
• Sales and suppliers were concentrated in Fiscal 2025, with two customers individually accounting for over 10% of total sales, representing a concentration risk.
• The Company's stock price has fluctuated considerably and has been volatile, with a 52-week range of $0.27 to $0.69 per share, and may not be sustained at higher levels.
• Management has broad discretion over the use of Company funds, and their judgments may not result in positive returns on investor investment.
• The Company is exposed to the risk of write-downs on the value of its inventory and other assets, as well as purchase commitment cancellation risk.
• The Company's accounting personnel may make unintentional errors, which could constitute a material weakness in internal controls over financial reporting.
• Uncertainty regarding the timing and certainty of receiving approximately $600 thousand in expected tax credits during Fiscal 2026, as claims are subject to IRS review and approval.

Risks

• The Company has incurred significant losses and has an accumulated deficit, and its ability to achieve profitability is highly uncertain.
• The Company may not be successful in its artificial intelligence initiatives, which could adversely affect its business, reputation, or financial results.
• The Company's cannabinoid medication makes it difficult to raise money as a public company due to incorrect classification as a 'cannabis company' by financial institutions.
• The Company may engage in strategic transactions (acquisitions, divestitures, partnerships) that could impact liquidity, increase expenses, and distract management, and may not be successful.
• Global operations in the U.S., Canada, Colombia, and India expose the Company to risks from currency fluctuations, economic conditions (including inflation), restrictive government actions, changes in intellectual property laws, trade regulations, tax laws, political/civil unrest, and natural disasters.
• The Company may face legal claims and liabilities, the extent of which can be difficult to estimate, potentially impacting financial condition and results of operations.
• The Company operates in a highly regulated industry, and significant, unforeseen changes in policy regarding cannabinoids or FDA approval processes may materially impact its business.
• The Company is inexperienced in conducting pre-clinical and clinical trials, which could lead to unanticipated or adverse outcomes.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, with uncertain outcomes, and may be delayed or terminated for various reasons.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, unpredictable, and may not result in approval for IGC-AD1 or other product candidates.
• The Company has concentrated its research and development efforts on Alzheimer's Disease, an area with limited success in drug development and a high failure rate (approximately 99.6%).
• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or impossible by factors outside the Company's control.
• The Company's product candidates may cause serious adverse events or undesirable side effects, which could delay or prevent marketing approval, require safety warnings, or limit sales.
• The Company's product candidates may be unable to achieve expected market acceptance, limiting revenue generation.
• Business interruptions (e.g., fire, theft, natural disasters, supply chain disruptions, loss of raw material) could delay product development and disrupt sales.
• Climate change concerns could disrupt businesses, adversely affect client activity levels, creditworthiness of counterparties, and damage reputation.
• Currency fluctuations may reduce the Company's assets and profitability due to operations in foreign countries.
• The Company's business relies heavily on its management team, and any unexpected loss of key officers may adversely affect operations.
• The Company's quarterly revenue, operating results, and profitability will vary due to seasonality, personnel changes, strategic decisions, and economic conditions.
• The Company may not successfully register its provisional patents with the USPTO, adversely affecting its ability to create a valuable product line.
• The Company may be unable to protect its intellectual property rights and/or licensed IP rights and may be subject to intellectual property litigation and infringement claims by third parties.
• The Company faces risks relating to health care privacy and security laws (e.g., HIPAA, HITECH), with potential for significant civil and criminal penalties for non-compliance.
• Reliance on third-party service providers for hosting and data, and any interruptions, security breaches, or failures in data collection could expose the Company to liability, increased costs, reduced revenue, and harm reputation.
• Risks associated with the manufacture of products, including industrial accidents, environmental events, labor disputes, supply chain disruptions, and quality control issues.
• Potential risks associated with the disposal of non-core assets, including impairment charges, termination costs, challenges in finding buyers, and regulatory/legal risks.
• The Company is exposed to the risk of write-downs on the value of its inventory and other assets, in addition to purchase commitment cancellation risk.
• The Company's accounting personnel may make unintentional errors, potentially leading to a material weakness in internal controls over financial reporting.
• The Company is subject to complex and changing laws and regulations worldwide related to climate change and ESG initiatives, which expose it to potential liabilities, increased costs, and other adverse effects.
• Future sales of common stock by the Company could cause its stock price to decline and dilute existing ownership.
• The Company's common stock price has fluctuated considerably and has recently reached high price levels, which may not be sustained.
• A possible short squeeze due to a sudden increase in demand for common stock that largely exceeds supply may lead to further price volatility.
• The Company's management team will have broad discretion over the use of Company funds, and their judgments may not result in positive returns.
• Publicly filed reports are subject to review by the SEC, and any significant changes or amendments required could result in material liability and adversely impact stock price.
• Maryland anti-takeover provisions and certain anti-takeover effects of the Company's Charter and Bylaws may inhibit a takeover at a premium price.
• Concentrated insider ownership (21.01% by executive officers and largest shareholders as of June 20, 2025) limits influence on corporate matters.

Future Outlook

IGC Pharma's future outlook is centered on advancing its lead drug candidate, IGC-AD1, by completing its Phase 2 clinical trial and initiating future studies to evaluate it as a disease-modifying therapy for Alzheimer's. The Company also plans to progress TGR-63 towards clinical trials and continue developing its AI-powered MINT-AD tool for early Alzheimer's detection and treatment personalization. Management anticipates an increase in R&D expenses as these development efforts gain momentum. The Company aims to broaden IGC-AD1's therapeutic potential beyond agitation to target core Alzheimer's symptoms, contingent on regulatory approval and clinical data. IGC Pharma hopes to leverage its R&D and intellectual property to develop groundbreaking, science-based products and believes that obtaining a first-in-class advantage could result in significant growth. The Company expects to raise additional capital for its trials through various financing sources, including equity issuances and non-dilutive funding opportunities, while continuing to optimize operational efficiency and maintain a robust financial position.

Management Comments

• "Our mission is to improve the lives of individuals affected by Alzheimers disease by addressing both its symptoms and the disease."
• "We believe that combining scientific innovation with operational execution, including leveraging our internal contract research organization, positions us to efficiently advance our pipeline toward commercialization, although there can be no assurance thereof."
• "We believe that additional investment in clinical trials, AI, R&D, facilities, marketing, advertising, and the acquisition of complementary products and businesses will be critical to the ongoing growth of the Life Sciences segment."
• "Although there can be no assurance, we believe these investments will fuel the development and delivery of innovative products that drive positive patient and customer experiences."
• "We hope to leverage our R&D and intellectual property to develop ground-breaking, science-based products that are proven effective through clinical trials, subject to FDA approval."
• "Although there can be no assurance, we believe this strategy can improve our existing products and lead to the creation of new products that can provide treatment options for multiple conditions, symptoms, and side effects."
• "By keeping trial costs below market averages while maintaining robust clinical standards, we believe we are well-positioned to deliver high-quality data and extend our cash runway, both critical to de-risking our development timeline and enhancing shareholder value, although there can be no assurance thereof."
• "While management believes these actions improve the Companys financial position, there can be no assurance that additional financing will be available on acceptable terms, or at all."
• "The Company expects to raise capital for its trials as and when it is able to do so, but there can be no assurance thereof."
• "In addition, there can be no assurance of the terms thereof, and any subsequent equity financing sought may have dilutive effects on our current shareholders."
• "While there is no guarantee that we will be successful, we are applying to non-dilutive funding opportunities such as Small Business Research and Development programs."
• "The Company estimates that its current cash and cash equivalents balance, with the working capital and investments, and with an available overdraft facility of $12 million from O-Bank, is sufficient to support operations beyond the twelve months following the date these consolidated financial statements and footnotes were issued."

Industry Context

IGC Pharma operates within the highly competitive and rapidly evolving biopharmaceutical industry, specifically targeting neurodegenerative diseases like Alzheimer's, an area with significant unmet medical needs and a historically high drug development failure rate (99.6%). The Company's focus on cannabinoid-based therapies places it within a complex regulatory environment, where federal and state laws regarding cannabis and hemp are still evolving. Its expansion into Artificial Intelligence (AI) and Machine Learning (ML) for drug discovery and clinical trial optimization aligns with a broader industry trend of leveraging advanced technologies to accelerate R&D and improve efficiency in pharmaceutical development.

Comparison to Industry Standards

• IGC-AD1's Phase 2 interim results for agitation in Alzheimer's disease showed a Cohen-Mansfield Agitation Inventory (CMAI) LS mean difference of -10.46 with a Cohen's d effect size of 0.79 at week 6, indicating a large and significant effect.
• This compares favorably to Brexpiprazole (Rexulti), the currently FDA-approved therapy for agitation in Alzheimer's dementia, which reported a moderate effect size (Cohen's d = 0.35) and showed separation from placebo only by Week 6 in its significantly larger Phase 3 trial.
• IGC-AD1 demonstrated faster symptom relief, with improvements observed as early as Week 2, whereas Brexpiprazole showed separation from placebo by Week 6.
• The Company has optimized its Phase 2 trial operations for IGC-AD1, achieving a cost per patient enrolled of approximately $70 thousand, which is significantly below industry norms for mid-stage neurodegenerative clinical trials, where average per-patient costs can exceed $100 thousand to $150 thousand.

Management Changes

Corporate Governance

Legal Proceedings

• Engineering and Consulting Group SAS et al. v IGC Pharma Inc., case file no. 110016 (Prosecutors Office 393 Sectional Economic Crimes Unit, Bogota, Colombia): A contractual dispute where IGC filed a complaint against four individuals for charges of fraud, falsification of a private document, and conspiracy to commit a crime. The case was reviewed in December 2023, and a hearing was scheduled and accepted for calendar 2024. During Fiscal 2025, the Company met with prosecutors to press for urgency in moving the case through the legal system.

Related Party Transactions

• On March 22, 2024, the Company entered into a Share Purchase Agreement (March 2024 SPA) with Bradbury Strategic Investment Fund A, resulting in approximately $3 million in gross proceeds. The individual holding voting and investment power in the investment manager is Mr. Loo See Yuen, Director of Bradbury Asset Management.
• On September 25, 2024, the Company entered into a Share Purchase Agreement (September 2024 SPA) with Moran Global Strategies, Inc., which is owned by James Moran, a director of IGC, for a total purchase price of $200,000.

Stakeholder Impact

• Shareholders: Face potential dilution from ongoing and future equity capital raises, but also stand to benefit from the potential significant value creation if IGC-AD1 achieves first-in-class advantage and regulatory approval. The stock price is subject to considerable volatility and potential short squeezes. No cash dividends are anticipated in the near future. Concentrated insider ownership limits individual shareholder influence.
• Patients and Caregivers: Stand to benefit significantly from the potential development of IGC-AD1 as a safe and effective treatment for agitation and sleep disturbances in Alzheimer's dementia, addressing a major unmet medical need. Future therapies like TGR-63 could offer disease-modifying effects, and AI tools like MINT-AD could improve early diagnosis and personalized treatment.
• Employees: Benefit from compensation and equity programs designed to retain talent and align with long-term shareholder value. The Company fosters a culture of collaboration and invests in employee development, while also implementing policies like the Insider Trading Policy that require compliance and may lead to disciplinary action for violations.
• Creditors: The Company has a working capital credit facility with O-Bank, Co., Ltd., and manages other liabilities, indicating ongoing financial obligations.
• Suppliers and Customers: The Company's sales and suppliers were concentrated in Fiscal 2025, which represents a risk of disruption if relationships with key parties are impaired.

Next Steps

• Complete the 146-patient Phase 2 CALMA clinical trial for IGC-AD1.
• Anticipate additional data readouts from the CALMA trial in late 2025, including further analysis of sleep-related outcomes.
• Initiate future studies evaluating IGC-AD1 as a disease-modifying therapy.
• Advance TGR-63 towards clinical trials, following favorable safety profile in preclinical studies.
• Plan toxicology studies for IGC-M3 in mid-2025.
• Finish the harmonization process and incorporate remaining databases for the Multimodal Interpretable Transformer for Alzheimer's Disease (MINT-AD) AI tool.
• Train the ensemble in the Mixture-of-Experts (MoE) architecture and test gating strategies for MINT-AD.
• Focus on understanding how cognitive abilities evolve over time and how modifiable risk factors lead to cognitive trajectory in the second phase of MINT-AD development.
• Deploy the final MINT-AD model for real-world validation and assessment of its impact on early detection and cognitive trajectory improvements in the last phase.
• Publish scientific findings in peer-reviewed journals to strengthen clinical credibility and visibility.
• Strategically allocate capital to enhance shareholder value by advancing the AD pipeline, optimizing operational efficiency, and maintaining a robust financial position.
• Continue additional investment in clinical trials, AI, R&D, facilities, marketing, advertising, and the acquisition of complementary products and businesses.
• Seek FDA approval for existing and future product candidates.
• Complete the sale of the non-operating land situated in Nagpur, India, for approximately $701 thousand.
• Expect to receive approximately $600 thousand in additional tax credits during Fiscal 2026.
• Continue to evaluate various financing sources and options to raise working capital to fund current research and development programs and operations.
• The Board of Directors will periodically review its leadership structure to determine if it continues to best serve IGC and its shareholders.
• The Company intends to establish a nominating and corporate governance committee in the future.

Key Dates

Recommendation

Keywords

Alzheimer's disease, IGC-AD1, Clinical trials, Agitation, Neurodegenerative, Artificial intelligence, Drug development, Biotechnology, Pharmaceutical, Hemp, Cannabinoid, SEC filing, 10-K, Corporate governance, Intellectual property, TGR-63, MINT-AD, Sleep disturbances